Kezar Life Sciences, Inc. (KZR)
NASDAQ: KZR · Real-Time Price · USD
6.38
-0.14 (-2.15%)
At close: Dec 20, 2024, 4:00 PM
6.36
-0.02 (-0.31%)
After-hours: Dec 20, 2024, 5:20 PM EST
Kezar Life Sciences Employees
Kezar Life Sciences had 58 employees as of December 31, 2023. The number of employees decreased by 26 or -30.95% compared to the previous year.
Employees
58
Change (1Y)
-26
Growth (1Y)
-30.95%
Revenue / Employee
n/a
Profits / Employee
-$1,651,345
Market Cap
46.55M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Cytosorbents | 186 |
| Fortress Biotech | 186 |
| Inovio Pharmaceuticals | 122 |
| Omega Therapeutics | 94 |
| iCAD, Inc. | 69 |
| vTv Therapeutics | 16 |
| Iterum Therapeutics | 14 |
| Nutriband | 13 |
KZR News
- 5 weeks ago - Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
- 6 weeks ago - Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR) - Business Wire
- 7 weeks ago - Kezar Life Sciences Announces 1-for-10 Reverse Stock Split - Business Wire
- 2 months ago - Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan - Business Wire
- 2 months ago - Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update - Business Wire
- 2 months ago - Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal - Business Wire
- 2 months ago - US FDA puts clinical hold on Kezar Life Sciences' lupus treatment trial - Reuters
- 2 months ago - Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis - Business Wire